US 12,187,792 B2
IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
Caroline Liot, New York, NY (US); and Frank Kuhnert, Cortlandt Manor, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Feb. 28, 2020, as Appl. No. 16/805,481.
Claims priority of provisional application 62/966,760, filed on Jan. 28, 2020.
Claims priority of provisional application 62/814,648, filed on Mar. 6, 2019.
Prior Publication US 2020/0283518 A1, Sep. 10, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/247 (2013.01) [A61K 39/3955 (2013.01); A61K 39/4636 (2023.05); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/244 (2013.01); C07K 16/28 (2013.01); C07K 16/2818 (2013.01); C07K 16/2866 (2013.01)] 40 Claims
OG exemplary drawing
 
1. A method of treating or inhibiting the growth of a tumor, comprising:
(a) selecting a subject with a Type 2 immunity-dependent cancer; and
(b) administering to the subject a therapeutically effective amount of an anti-interleukin-4 receptor (IL-4R) antibody and a therapeutically effective amount of an anti-programmed death 1 (PD-1) antibody;
wherein:
the anti-IL-4R antibody comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2; and
the anti-PD-1 antibody comprises a HCVR comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) and a LCVR comprising three light chain CDRs (LCDR1, LCDR2 and LCDR3), wherein: HCDR1 has the amino acid sequence of SEQ ID NO: 13; HCDR2 has the amino acid sequence of SEQ ID NO: 14; HCDR3 has the amino acid sequence of SEQ ID NO: 15; LCDR1 has the amino acid sequence of SEQ ID NO: 16; LCDR2 has the amino acid sequence of SEQ ID NO: 17; and LCDR3 has the amino acid sequence of SEQ ID NO: 18.